{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:10:28Z","timestamp":1785841828171,"version":"3.56.0"},"reference-count":28,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Background: Anticoagulants are life-saving medicines that can prevent strokes for patients diagnosed with atrial fibrillation (AF) as well as treating patients with venous thromboembolism (VTE), but when used incorrectly, they are frequently associated with patient harm. Aim: To evaluate the impact of community pharmacy teams on optimising patient knowledge and awareness and improving medication safety from the use of anticoagulants. Methods: Two national audits, consisting of 17 questions assessing and improving patients\u2019 understanding of anticoagulant therapy, identifying high-risk patients, and contacting prescribers when clinically appropriate were incentivised for England\u2019s community pharmacies in 2021\u20132022 and 2023\u20132024 using the Pharmacy Quality Scheme (PQS) commissioned by NHS England. Results: Approximately 11,000 community pharmacies audited just under a quarter of a million patients in total, whilst making almost 150,000 interventions for patients taking oral anticoagulants, i.e., identifying and addressing medication issues which could increase the risk of bleeding\/harm. Out of the 111,195 patients audited in 2021\u20132022, only 24,545 (23%) patients were prescribed vitamin K antagonists. The remaining patients were prescribed direct oral anticoagulants (DOACs). By 2023\u20132024, this decreased to 17,043 (16%) patients. Most patients knew that they were prescribed an anticoagulant (95.6%, 106,255 in 2021\u20132022 and 96.5%, 101,006 in 2023\u20132024, p &lt; 0.001). Discussion: The audits resulted in a statistically significant increase in patients with a standard yellow anticoagulant alert card, as identified in audit 2 (73,901 66.5% in 2021\u20132022 to 76,735, 73.3% in 2023\u20132024, p &lt; 0.001). Furthermore, fewer patients were prescribed concurrent antiplatelets with an anticoagulant (6021; 4.6% in 2021\u20132022 to 4975; 4% in 2023\u20132024, p &lt; 0.001). Although there was an increase in the number of patients prescribed NSAIDs with anticoagulants, more of these patients were also prescribed gastroprotection concurrently (927 77.2% in 2021\u20132022 to 1457 84.1% in 2023\u20132024, p &lt; 0.05). The majority of patients on warfarin had their blood checked within 12 weeks. Further there was an increase for these patients in the percentage of people prescribed VKAs who knew dietary changes can affect their anticoagulant medicine (16,764 67.4% in 2021\u20132022 to 12,594 73.9% in 2023\u20132024 p &lt; 0.001). Conclusions: Community pharmacy teams are well placed in educating and counselling patients on the safe use of anticoagulants and ensuring that all patients are correctly monitored.<\/jats:p>","DOI":"10.3390\/pharmacy12050134","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T11:12:13Z","timestamp":1724929933000},"page":"134","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An Evaluation of Oral Anticoagulant Safety Indicators by England\u2019s Community Pharmacies"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-7710","authenticated-orcid":false,"given":"Sejal","family":"Parekh","sequence":"first","affiliation":[{"name":"Primary Care Strategy and NHS Contracts Group, Primary, Community and Personalised Care Directorate, NHS England, London SE1 8UG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingqian","family":"Xu","sequence":"additional","affiliation":[{"name":"Pharmacy, Optometry and Dental Strategic Analysis Group, Primary, Community and Personalised Care Directorate, NHS England, London SE1 8UG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Livingstone","sequence":"additional","affiliation":[{"name":"NHS Specialist Pharmacy Services, The Causeway, Ground Floor, Worthing BN12 6BT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"ref_1","unstructured":"NHS (2019, July 01). Anticoagulant Medicines. Available online: https:\/\/www.nhs.uk\/conditions\/anticoagulants\/."},{"key":"ref_2","unstructured":"World Health Organisation (2024, March 18). World Health Organisation: Medication safety in high-risk situations. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-UHC-SDS-2019.10."},{"key":"ref_3","unstructured":"NPS Agency (2019, June 02). Actions That Can Make Anticoagulant Therapy Safer: Alert and Other Information. 28 March 2007, Available online: https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20180501195611\/http:\/www.nrls.npsa.nhs.uk\/resources\/search-by-audience\/community-nurse\/?entryid45=59814&cord=ASC&p=2."},{"key":"ref_4","unstructured":"NHS Business Services Authority (2024, March 31). Medication Safety: ePACT2. Available online: https:\/\/www.nhsbsa.nhs.uk\/access-our-data-products\/epact2\/dashboards-and-specifications\/medication-safety."},{"key":"ref_5","unstructured":"NHS Business Services Authority (2023, July 31). NHSBSA Catalyst\u2014Public Insight Portal\u2014Catalyst: 03 Dashboard\u2014Medication Safety Indicators GIB03: [Hospital admission] Admitted and Prescribed an Oral Anticoagulant + Anti-Platelet without Gastro-Protection. Medication Safety Dashboards 2023. Available online: https:\/\/www.nhsbsa.nhs.uk\/access-our-data-products\/catalyst."},{"key":"ref_6","unstructured":"NHS Business Services Authority (2024, May 25). EPACT2 Data. Available online: https:\/\/www.nhsbsa.nhs.uk\/access-our-data-products\/epact2."},{"key":"ref_7","unstructured":"NHS England, and NHS Improvement (2020). Clinical guide for the management of anticoagulant services during the coronovirus pandemic. Publ. Approv. Ref., 1559, 1\u201314."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e001784","DOI":"10.1136\/openhrt-2021-001784","article-title":"OpenSAFELY: Impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic","volume":"8","author":"Curtis","year":"2021","journal-title":"Open Heart"},{"key":"ref_9","unstructured":"Medicines & Healthcare Products Regulatory Agency (2022, June 15). Warfarin and Other Anticoagulant\u2014Monitoring of Patients during COVID-19 Pandemic. 13 October 2020, Available online: https:\/\/www.gov.uk\/government\/publications\/warfarin-and-other-anticoagulants-monitoring-of-patients-during-the-covid-19-pandemic\/warfarin-and-other-anticoagulants-monitoring-of-patients-during-the-covid-19-pandemic."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11096-020-01134-w","article-title":"Evaluation of patients\u2019 knowledge about oral anticoagulant medicines and use of alert cards by community pharmacists","volume":"43","author":"Jani","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/bcp.12718","article-title":"A systematic review of the role of community pharmacies in improving the transition from secondary to primary care","volume":"80","author":"Nazar","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_12","unstructured":"NICE (2019, September 21). Medicines Optimisation: The Safe and Effective Use of Medicines to Enable the Best Possible Outcomes. Available online: https:\/\/www.nice.org.uk\/guidance\/NG5\/chapter\/1-Recommendations."},{"key":"ref_13","unstructured":"NHS England (2022, November 08). Pharmacy Quality Scheme. Available online: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/09\/PRN00176-pharmacy-quality-scheme-guidance-23-24-v2.pdf."},{"key":"ref_14","unstructured":"NHS England (2024, July 08). Community Pharmacy Oral Anticoagulant Safety Audit 2021\u20132022. March 2023. Available online: https:\/\/www.england.nhs.uk\/publication\/community-pharmacy-oral-anticoagulant-safety-audit-2021-22\/."},{"key":"ref_15","unstructured":"Joint Formulary Committee (2024, May 22). British National Formulary: BNF British National Formulary\u2014NICE. Available online: https:\/\/bnf.nice.org.uk\/interactions\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"BJGPO.2023.0163","DOI":"10.3399\/BJGPO.2023.0163","article-title":"Safety of direct-acting oral anticoagulant (DOAC) prescribing: OpenSAFELY-TPP analysis of 20.5 million adults\u2019 electronic health records","volume":"8","author":"Homan","year":"2024","journal-title":"BJGP Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.5603\/KP.a2018.0069","article-title":"Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists","volume":"76","author":"Sobieraj","year":"2018","journal-title":"Pol. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1345\/aph.1A198","article-title":"Relationship between patients\u2019 warfarin knowledge and anticoagulation control","volume":"37","author":"Tang","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Berdi, F., Tadlaoui, Y., Fahry, A., Zbir, M., Bennana, A., and Bousliman, Y. (2017). CP-188 Evaluation of Patient\u2019s Knowledge about Vitamin K Antagonist Treatment, British Medical Journal Publishing Group.","DOI":"10.1136\/ejhpharm-2017-000640.186"},{"key":"ref_23","unstructured":"England, N. (2024, July 08). Network Contract Directed Enhanced Service\u2014Investment and Impact Fund 2022\/23: Updated Guidance. 30 September 2022. Available online: https:\/\/www.england.nhs.uk\/publication\/network-contract-directed-enhanced-service-investment-and-impact-fund-2022-23-updated-guidance\/."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e002002","DOI":"10.1136\/bmjoq-2022-002002","article-title":"Evaluation of the England Community Pharmacy Quality Scheme (2018\u20132019 and 2019\u20132020) in reducing harm from NSAIDs in older patients","volume":"12","author":"Parekh","year":"2023","journal-title":"BMJ Open Qual."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Parekh, S., Hayes, C.V., Loader, J., Ashiru-Oredope, D., Hand, K., Hicks, G., and Lecky, D. (2023). The Use of the TARGET Antibiotic Checklist to Support Antimicrobial Stewardship in England\u2019s Community Pharmacies. Antibiotics, 12.","DOI":"10.3390\/antibiotics12040647"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Parekh, S., Hand, K., Xu, L., Roberts, V., Pursey, F., Ashiru-Oredope, D., and Lecky, D.M. (2023). Responding to Urinary Tract Infection Symptoms in England\u2019s Community Pharmacies. Antibiotics, 12.","DOI":"10.3390\/antibiotics12091383"},{"key":"ref_27","unstructured":"World Health Organization (2019, June 04). The Third Global Patient Safety Challenge: Tackling Medication Related Harm. Available online: https:\/\/www.who.int\/publications\/i\/item\/BLT.17.198002."},{"key":"ref_28","unstructured":"NHS Health Research Authority: Medical Research Authority: UK Research and Innovation (2024, July 08). Is My Study Research?. Available online: https:\/\/www.hra-decisiontools.org.uk\/research\/."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/12\/5\/134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:45:15Z","timestamp":1760111115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/12\/5\/134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["pharmacy12050134"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy12050134","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}